Evidence map›Paper›PMID 41255992›Full record

ArticleResearch square2025

Illuminating the Druggable Human Proteome with an AI Protein Profiling Platform.

Guy W Dayhoff, Daniel Kortzak, Ruibin Liu, Mingzhe Shen, Zhong-Yin Zhang, Jana Shen

Abstract readPreprint
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Guy W DayhoffDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, U.S.A.
Daniel KortzakDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, U.S.A.
Ruibin LiuDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, U.S.A.
Mingzhe ShenDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, U.S.A.
Zhong-Yin ZhangBorch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907, U.S.A.ORCID 0000-0001-5527-7910
Jana ShenDepartment of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, U.S.A.

Funding

Structure/Function of Protein Tyrosine PhosphatasesR01CA069202 · NCI · YESHIVA UNIVERSITY · PI Zhong-Yin Zhang · 1996 to 2026
$7.3M
Molecular mechanisms of proton-coupled dynamic processes in biologyR35GM148261 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE · PI Jana Shen · 2023 to 2026
$1.5M
A Multi-pronged Computational Approach to Advance Kinase Drug DiscoveryR01CA256557 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI SHEN, JANA · 2021 to 2024
$1.4M
NCI NIH HHS R01 CA069202NCI NIH HHS R01 CA256557NIGMS NIH HHS R35 GM148261
6 · The paper itself

Abstract

Creating a ligandable atlas for the proteome would transform our understanding of protein functions and accelerate therapeutic discovery; however, proteomic approaches are constrained by insufficient proteome coverage and data heterogeneity, while existing machine learning (ML) models have limited power due to structural dependencies and heterogeneous experimental labels. Here we developed AiPP, a multimodal AI platform that predicts and characterizes ligand interaction sites directly from protein sequence. AiPP is powered by the evolutionary-scale protein large language models (LLMs) and leverages two harmonized ML training sets derived from the new databases comprising cysteine ligandability from activity-based protein profiling (ABPP) studies and reversible binding evidenced from co-crystal structures. We developed a LLM representation based clustering framework to interrogate, reconcile, and augment experimental labels in both databases. Two complementary protocols were implemented to iteratively expand the training data while improving model performance. Although trained exclusively on ABPP data, AiPP recovers 80% (Top-1) of cysteine liganding events from cocrystal structures, with 84% AUPRC and 89% AUROC. AiPP recapitulates consistently and heterogeneously liganded cysteines across cancer cell lines and reliably identifies dynamic, ligandable pockets in "undruggable" transcription factors. Remarkably, AiPP accurately predicts active-site and allosteric cysteines in protein tyrosine phosphatases that were undetected by ABPP. Finally, we applied AiPP to the entire human proteome, identifying ligandable sites in proteins that were undetected or unliganded by ABPP, including an allosteric site in MC3R, which is a therapeutic target for treatment of eating disorder and obesity. This proteomewide covalent ligandability atlas (version 1.0) is anticipated to guide future development of chemical probes and pharmaceutical modulators, particularly for understudied proteins and currently undruggable targets. The LLM-based approach to interrogate large-scale heterogeneous data is broadly applicable to protein research and development of proteomics-derived ML models for diverse applications.

Identifiers

PMID41255992
PMCPMC12622158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.